Literature DB >> 32165206

Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center.

Francoise Galateau Salle1, Nolwenn Le Stang2, Franck Tirode3, Pierre Courtiol4, Andrew G Nicholson5, Ming-Sound Tsao6, Henry D Tazelaar7, Andrew Churg8, Sanja Dacic9, Victor Roggli10, Daniel Pissaloux11, Charles Maussion4, Matahi Moarii4, Mary Beth Beasley12, Hugues Begueret13, David B Chapel14, Marie Christine Copin15, Allen R Gibbs16, Sonja Klebe17, Sylvie Lantuejoul2, Kazuki Nabeshima18, Jean-Michel Vignaud19, Richard Attanoos16, Luka Brcic20, Frederique Capron21, Lucian R Chirieac22, Francesca Damiola2, Ruth Sequeiros2, Aurélie Cazes23, Diane Damotte24, Armelle Foulet25, Sophie Giusiano-Courcambeck26, Kenzo Hiroshima27, Veronique Hofman28, Aliya N Husain14, Keith Kerr29, Alberto Marchevsky30, Severine Paindavoine3, Jean Michel Picquenot31, Isabelle Rouquette32, Christine Sagan33, Jennifer Sauter34, Francoise Thivolet35, Marie Brevet35, Philippe Rouvier21, William D Travis34, Gaetane Planchard36, Birgit Weynand37, Thomas Clozel4, Gilles Wainrib4, Lynnette Fernandez-Cuesta38, Jean-Claude Pairon39, Valerie Rusch40, Nicolas Girard41.   

Abstract

INTRODUCTION: Histologic subtypes of malignant pleural mesothelioma are a major prognostic indicator and decision denominator for all therapeutic strategies. In an ambiguous case, a rare transitional mesothelioma (TM) pattern may be diagnosed by pathologists either as epithelioid mesothelioma (EM), biphasic mesothelioma (BM), or sarcomatoid mesothelioma (SM). This study aimed to better characterize the TM subtype from a histological, immunohistochemical, and molecular standpoint. Deep learning of pathologic slides was applied to this cohort.
METHODS: A random selection of 49 representative digitalized sections from surgical biopsies of TM was reviewed by 16 panelists. We evaluated BAP1 expression and CDKN2A (p16) homozygous deletion. We conducted a comprehensive, integrated, transcriptomic analysis. An unsupervised deep learning algorithm was trained to classify tumors.
RESULTS: The 16 panelists recorded 784 diagnoses on the 49 cases. Even though a Kappa value of 0.42 is moderate, the presence of a TM component was diagnosed in 51%. In 49% of the histological evaluation, the reviewers classified the lesion as EM in 53%, SM in 33%, or BM in 14%. Median survival was 6.7 months. Loss of BAP1 observed in 44% was less frequent in TM than in EM and BM. p16 homozygous deletion was higher in TM (73%), followed by BM (63%) and SM (46%). RNA sequencing unsupervised clustering analysis revealed that TM grouped together and were closer to SM than to EM. Deep learning analysis achieved 94% accuracy for TM identification.
CONCLUSION: These results revealed that the TM pattern should be classified as non-EM or at minimum as a subgroup of the SM type.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Histology; Mesothelioma; Surgery; Systemic treatment

Mesh:

Substances:

Year:  2020        PMID: 32165206      PMCID: PMC8864581          DOI: 10.1016/j.jtho.2020.01.025

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  38 in total

1.  BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas.

Authors:  Harry C Hwang; Shawna Pyott; Stephanie Rodriguez; Ashlie Cindric; April Carr; Carmen Michelsen; Kim Thompson; Christopher H Tse; Allen M Gown; Andrew Churg
Journal:  Am J Surg Pathol       Date:  2016-05       Impact factor: 6.394

2.  Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations.

Authors:  Raphael Bueno; Eric W Stawiski; Leonard D Goldstein; Steffen Durinck; Assunta De Rienzo; Zora Modrusan; Florian Gnad; Thong T Nguyen; Bijay S Jaiswal; Lucian R Chirieac; Daniele Sciaranghella; Nhien Dao; Corinne E Gustafson; Kiara J Munir; Jason A Hackney; Amitabha Chaudhuri; Ravi Gupta; Joseph Guillory; Karen Toy; Connie Ha; Ying-Jiun Chen; Jeremy Stinson; Subhra Chaudhuri; Na Zhang; Thomas D Wu; David J Sugarbaker; Frederic J de Sauvage; William G Richards; Somasekar Seshagiri
Journal:  Nat Genet       Date:  2016-02-29       Impact factor: 38.330

3.  Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes.

Authors:  Andrew Churg; Kazuki Nabeshima; Greta Ali; Rossella Bruno; Lynnette Fernandez-Cuesta; Francoise Galateau-Salle
Journal:  Lung Cancer       Date:  2018-07-30       Impact factor: 5.705

Review 4.  Progress in the Management of Malignant Pleural Mesothelioma in 2017.

Authors:  Amanda J McCambridge; Andrea Napolitano; Aaron S Mansfield; Dean A Fennell; Yoshitaka Sekido; Anna K Nowak; Thanyanan Reungwetwattana; Weimin Mao; Harvey I Pass; Michele Carbone; Haining Yang; Tobias Peikert
Journal:  J Thorac Oncol       Date:  2018-03-08       Impact factor: 15.609

5.  p16 Deletion in sarcomatoid tumors of the lung and pleura.

Authors:  Naobumi Tochigi; Richard Attanoos; Lucian R Chirieac; Timothy Craig Allen; Philip T Cagle; Sanja Dacic
Journal:  Arch Pathol Lab Med       Date:  2013-05       Impact factor: 5.534

6.  Deep learning-based classification of mesothelioma improves prediction of patient outcome.

Authors:  Pierre Courtiol; Charles Maussion; Françoise Galateau-Sallé; Gilles Wainrib; Thomas Clozel; Matahi Moarii; Elodie Pronier; Samuel Pilcer; Meriem Sefta; Pierre Manceron; Sylvain Toldo; Mikhail Zaslavskiy; Nolwenn Le Stang; Nicolas Girard; Olivier Elemento; Andrew G Nicholson; Jean-Yves Blay
Journal:  Nat Med       Date:  2019-10-07       Impact factor: 53.440

7.  Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.

Authors:  Di Wu; Kenzo Hiroshima; Toshikazu Yusa; Daisuke Ozaki; Eitetsu Koh; Yasuo Sekine; Shinji Matsumoto; Kazuki Nabeshima; Ayuko Sato; Tohru Tsujimura; Hisami Yamakawa; Yuji Tada; Hideaki Shimada; Masatoshi Tagawa
Journal:  Ann Diagn Pathol       Date:  2016-10-22       Impact factor: 2.090

8.  New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.

Authors:  F Galateau Salle; N Le Stang; A G Nicholson; D Pissaloux; A Churg; S Klebe; V L Roggli; H D Tazelaar; J M Vignaud; R Attanoos; M B Beasley; H Begueret; F Capron; L Chirieac; M C Copin; S Dacic; C Danel; A Foulet-Roge; A Gibbs; S Giusiano-Courcambeck; K Hiroshima; V Hofman; A N Husain; K Kerr; A Marchevsky; K Nabeshima; J M Picquenot; I Rouquette; C Sagan; J L Sauter; F Thivolet; W D Travis; M S Tsao; B Weynand; F Damiola; A Scherpereel; J C Pairon; S Lantuejoul; V Rusch; N Girard
Journal:  J Thorac Oncol       Date:  2018-04-30       Impact factor: 15.609

Review 9.  The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification.

Authors:  Francoise Galateau-Salle; Andrew Churg; Victor Roggli; William D Travis
Journal:  J Thorac Oncol       Date:  2016-02       Impact factor: 15.609

10.  Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.

Authors:  Arnaud Scherpereel; Julien Mazieres; Laurent Greillier; Sylvie Lantuejoul; Pascal Dô; Olivier Bylicki; Isabelle Monnet; Romain Corre; Clarisse Audigier-Valette; Myriam Locatelli-Sanchez; Olivier Molinier; Florian Guisier; Thierry Urban; Catherine Ligeza-Poisson; David Planchard; Elodie Amour; Franck Morin; Denis Moro-Sibilot; Gérard Zalcman
Journal:  Lancet Oncol       Date:  2019-01-16       Impact factor: 41.316

View more
  14 in total

Review 1.  Deep learning in histopathology: the path to the clinic.

Authors:  Jeroen van der Laak; Geert Litjens; Francesco Ciompi
Journal:  Nat Med       Date:  2021-05-14       Impact factor: 53.440

Review 2.  Designing deep learning studies in cancer diagnostics.

Authors:  Andreas Kleppe; Ole-Johan Skrede; Sepp De Raedt; Knut Liestøl; David J Kerr; Håvard E Danielsen
Journal:  Nat Rev Cancer       Date:  2021-01-29       Impact factor: 60.716

Review 3.  Challenges in lung and thoracic pathology: molecular advances in the classification of pleural mesotheliomas.

Authors:  Lynnette Fernandez-Cuesta; Lise Mangiante; Nicolas Alcala; Matthieu Foll
Journal:  Virchows Arch       Date:  2021-01-07       Impact factor: 4.064

Review 4.  Pleural mesothelioma classification update.

Authors:  Mary Beth Beasley; Francoise Galateau-Salle; Sanja Dacic
Journal:  Virchows Arch       Date:  2021-01-21       Impact factor: 4.064

Review 5.  Pleural mesothelioma classification-update and challenges.

Authors:  Sanja Dacic
Journal:  Mod Pathol       Date:  2021-08-31       Impact factor: 7.842

Review 6.  Immunotherapy approaches for malignant pleural mesothelioma.

Authors:  Dean A Fennell; Sean Dulloo; James Harber
Journal:  Nat Rev Clin Oncol       Date:  2022-07-01       Impact factor: 65.011

Review 7.  When the Diagnosis of Mesothelioma Challenges Textbooks and Guidelines.

Authors:  Giulio Rossi; Fabio Davoli; Venerino Poletti; Alberto Cavazza; Filippo Lococo
Journal:  J Clin Med       Date:  2021-05-30       Impact factor: 4.241

Review 8.  Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma.

Authors:  Francesca Napoli; Angela Listì; Vanessa Zambelli; Gianluca Witel; Paolo Bironzo; Mauro Papotti; Marco Volante; Giorgio Scagliotti; Luisella Righi
Journal:  Cancers (Basel)       Date:  2021-05-24       Impact factor: 6.639

Review 9.  Malignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge.

Authors:  David Michael Abbott; Chandra Bortolotto; Silvia Benvenuti; Andrea Lancia; Andrea Riccardo Filippi; Giulia Maria Stella
Journal:  Cancers (Basel)       Date:  2020-05-07       Impact factor: 6.639

10.  Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma.

Authors:  Clément Meiller; François Montagne; Theo Z Hirsch; Stefano Caruso; Julien de Wolf; Quentin Bayard; Jean-Baptiste Assié; Léa Meunier; Yuna Blum; Lisa Quetel; Laure Gibault; Ecaterina Pintilie; Cécile Badoual; Sarah Humez; Françoise Galateau-Sallé; Marie-Christine Copin; Eric Letouzé; Arnaud Scherpereel; Jessica Zucman-Rossi; Françoise Le Pimpec-Barthes; Marie-Claude Jaurand; Didier Jean
Journal:  Genome Med       Date:  2021-07-14       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.